公开(公告)号：EP2550968A1

公开(公告)日：2013-01-30

申请号：EP12189943.9

申请日：2005-02-08

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center ,  The Regents of the University of California

发明人： Kolodney, Michael S. ,  Rotunda, Adam M.

IPC分类号： A61K31/575 ,  A61P3/00 ,  A61Q19/06 ,  A61K31/222 ,  A61K31/60 ,  A61K45/06 ,  A61K9/00

CPC分类号： A61K31/575 ,  A61K8/63 ,  A61K9/0019 ,  A61K31/685 ,  A61K45/06 ,  A61K2800/30 ,  A61K2800/91 ,  A61Q19/06 ,  A61K2300/00

摘要： Compositions and methods useful in the non-surgical removal of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion agents and pharmaceutically acceptable excipients but do not contain phosphotidylcholine. The pharmacologically active detergents compositions are useful for treating localized accumulations of fat including lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.

摘要翻译： 组合物和方法及其使用的药理学活性洗涤剂在有需要的病人的非外科手术去除局部脂肪沉积物的有用的游离缺失盘。 药理活性的洗涤剂组合物可另外包括抗炎剂，止痛剂，分散剂和药学上可接受的赋形剂，但不包含磷脂酰胆碱。 药理活性的洗涤剂组合物用于治疗包括下眼睑脂肪疝，脂肪代谢障碍和脂肪堆积橘皮相关的，并且不需要外科手术的局部脂肪堆积有用：如吸脂术。

公开(公告)号：EP1507555B1

公开(公告)日：2012-12-19

申请号：EP03726601.2

申请日：2003-05-05

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

发明人： KAKKIS, Emil, D. ,  PASSAGE, Merry ,  LESTER, Thomas ,  YANG, Rebecca ,  TANAKA, Christopher

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61K38/00 ,  A61K38/28 ,  A61K38/17 ,  A61K38/43

CPC分类号： A61K39/00 ,  A61K31/522 ,  A61K31/7024 ,  A61K38/00 ,  A61K38/11 ,  A61K38/13 ,  A61K2300/00

公开(公告)号：EP2422789A1

公开(公告)日：2012-02-29

申请号：EP11166225.0

申请日：2005-02-08

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center ,  The Regents of the University of California

发明人： Kolodney, Michael S. ,  Rotunda, Adam M.

IPC分类号： A61K31/575 ,  A61K31/765 ,  A61K31/205 ,  A61P3/00 ,  A61Q19/06

CPC分类号： A61K31/575 ,  A61K8/63 ,  A61K9/0019 ,  A61K31/685 ,  A61K45/06 ,  A61K2800/30 ,  A61K2800/91 ,  A61Q19/06 ,  A61K2300/00

摘要： Compositions and methods useful in the non-surgical removal of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion agents and pharmaceutically acceptable excipients but do not contain phosphotidylcholine. The pharmacologically active detergents compositions are useful for treating localized accumulations of fat including lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.

摘要翻译： 公开了可用于使用药理活性洗涤剂非需要的患者非手术去除局部脂肪沉积物的组合物和方法。 药理活性的洗涤剂组合物可另外包含抗炎剂，止痛剂，分散剂和药学上可接受的赋形剂，但不含磷脂酰胆碱。 药理活性洗涤剂组合物可用于治疗脂肪的局部积聚，包括下眼睑脂肪突出症，脂肪营养不良和与脂肪团相关的脂肪沉积物，并且不需要外科手术如抽脂。

公开(公告)号：EP2408804A1

公开(公告)日：2012-01-25

申请号：EP10753820.9

申请日：2010-03-19

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

发明人： IBRAHIM, Ashraf, S. ,  SPELLBERG, Brad, J. ,  FU, Yue ,  EDWARDS, John, E.

IPC分类号： C07K14/00 ,  C07K16/00

CPC分类号： C07K16/14 ,  A61K2039/505 ,  C12N9/00 ,  C12N15/1138 ,  C12N2310/14

摘要： The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant.

摘要翻译： 本发明提供治疗和预防包括毛霉菌病在内的真菌疾病或病症的治疗组合物和方法。 本发明的治疗方法和组合物包括具有FTR多肽或多肽的抗原性片段的疫苗组合物; 包含与FTR序列的至少18个连续核苷酸基本互补的核苷酸序列的载体; 反义词; 小干扰RNA或FTR的抗体抑制剂。 本发明的疫苗组合物可以进一步包含佐剂。

公开(公告)号：EP1792983A1

公开(公告)日：2007-06-06

申请号：EP06011595.3

申请日：2000-11-09

申请人： Biomarin Pharmaceutical Inc. ,  Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

发明人： Henstrand, John M. ,  Qin, Minmin ,  Chan, Wia-Pan ,  Chen, Lin ,  Fitzpatrick, Paul A. ,  Wendt, Dan J. ,  Zecherle, Gary N. ,  Starr, Christopher M. ,  Kakkis, Emil D. ,  Tanamachi, Becky

IPC分类号： C12N9/24 ,  A61K38/47 ,  A61P3/00

CPC分类号： C12N9/88 ,  A61K38/47 ,  A61K48/00 ,  C12N9/2402 ,  C12Y302/01014 ,  C12Y302/01075 ,  C12Y302/01076 ,  C12Y402/02004

摘要： The present invention provides a recombinant human α-L-iduronidase and biologically active fragments and mutants thereof, large scale methods to produce and purify commercial grade recombinant human, α-L-iduronidase enzyme as well as methods to treat certain genetic disorders including α-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).

摘要翻译： 本发明提供了重组人±-L-艾杜糖醛酸酶及其生物活性片段和突变体，大规模生产和纯化商业级重组人，±-L-艾杜糖醛酶的方法以及治疗某些遗传疾病的方法，包括± L-iduronidase缺乏和粘多糖贮积症I（MPS 1）。

公开(公告)号：EP2380576B1

公开(公告)日：2020-04-08

申请号：EP11166230.0

申请日：2005-05-19

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center ,  The Regents of the University of California

发明人： Kolodney, Michael S. ,  Rotunda, Adam M.

IPC分类号： A61Q19/06 ,  A61K31/575 ,  A61P3/04

公开(公告)号：EP3505181A1

公开(公告)日：2019-07-03

申请号：EP18248241.4

申请日：2018-12-28

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center ,  Phoenix Nest Inc.

发明人： DICKSON, Patricia ,  CHOU, Tsui-Fen ,  EKINS, Sean ,  KAN, Shih-Hsin ,  LE, Steven ,  MOEN, Derek R.

IPC分类号： A61K38/46 ,  C12N9/16

摘要： The present disclosure relates to compositions for use in a method of treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mucopolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a recombinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the enzymatic activity of the human GNS protein. The composition can be tested in a testing buffer comprising less than 500 mM sodium, less than 100 mM citrate, less than 100 mM phosphate, less than 100 mM sulfate, and at least 0.005% Triton X-100 at a pH of about 5.6.

公开(公告)号：EP1469879B1

公开(公告)日：2019-03-20

申请号：EP03710635.8

申请日：2003-01-03

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center ,  Trustees of Boston University

发明人： SMITH, Terry, J. ,  CRUIKSHANK, William, W.

IPC分类号： A61K38/19 ,  A61K39/395 ,  C12Q1/68 ,  G01N33/53

公开(公告)号：EP3452041A1

公开(公告)日：2019-03-13

申请号：EP17763818.6

申请日：2017-03-06

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

发明人： REHAN, Virender K. ,  TORDAY, John S. ,  WALTHER, Frans J. ,  WARING, Alan J. ,  GORDON, Larry M.

IPC分类号： A61K31/4439 ,  A61K9/12

公开(公告)号：EP3373958A1

公开(公告)日：2018-09-19

申请号：EP16865148.7

申请日：2016-11-11

申请人： Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

发明人： BARDAG-GORCE, Fawzia

IPC分类号： A61K38/55 ,  A61K31/00 ,  A61K38/16

CPC分类号： A61K31/7048 ,  A61K31/222 ,  A61K31/336 ,  A61K31/4015 ,  A61K31/407 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/5377 ,  A61K31/69

摘要： Disclosed herein are methods and compositions useful for preventing or reducing corneal haze of opacification resulting from Limbal Stem Cell Deficiency (LSCD). The invention comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. The invention also comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. In addition, the invention comprises a method of administering to a subject suffering from corneal opacification with a sufficient amount of proteasome modulator, resulting in reduction of Keratin proteins in the cornea of the subject.